Analysts expect GeneDx Holdings Corp. to report a consensus revenue of $122.93 million and earnings per share (EPS) of $0.07 for Q3 2026, with the current stock price of $61.25 trading significantly below the average analyst target of $90.86. Investors are closely monitoring the company's path to sustained profitability, particularly its ability to build on the adjusted net income milestone reached in the previous quarter.
The core focus remains on the continued shift toward higher-margin whole exome and genome sequencing (WES/WGS) services, which now represent nearly half of the company's testing volume. Management has reaffirmed guidance for at least 30% year-over-year volume growth in these core diagnostic segments, supported by recent revenue cycle improvements and a significant expansion of the sales force.